Search - tctmd.com

Displaying 921 - 940 of 943

Sort: Relevancy | Date

News Daily News

El Pantoprazol No es Necesariamente un PPI Seguro para Pacientes a Tratamiento con Terapia Antiplaquetaria Doble

L.A. McKeown

August 01, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

News Daily News

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

L.A. McKeown

March 12, 2012

News Daily News

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

L.A. McKeown

March 12, 2012

News Daily News

Meta-Analysis: Adjunctive Cilostazol Lowers Repeat Revascularization After PCI

Caitlin E. Cox

March 07, 2012

News Daily News

Meta-Análisis: Cilostazol Adyuvante Reduce la Necesidad de Volver a Revascularizar tras una PCI

Caitlin E. Cox

March 07, 2012

News Daily News

Nuevo Análisis PLATO: Las dosis de Aspirina podrían Explicar los Resultados Discordantes de Norteamérica

Caitlin E. Cox

March 06, 2012

News Daily News

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

Caitlin E. Cox

March 06, 2012

Presentation ISET 2012

The Value of Dual Antiplatelet Therapy During and After Endovascular Procedures: Results of a Randomized Trial - The MIRROR Study

Presenter: Gunnar Tepe

January 17, 2012

News Daily News

Six Months Sufficient for Dual Antiplatelet Therapy

Jason Kahn

October 17, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

News Daily News

Prior Medication Adherence Predicts Post-PCI Clopidogrel Compliance

July 20, 2011

News Daily News

Adding Omega-3 Fatty Acids to Dual Antiplatelet Therapy May Reduce Thrombotic Risk

Leah Lawrence

May 26, 2011

News Daily News

Since COURAGE, Little Change in Optimal Medical Therapy for Stable PCI Patients

Caitlin E. Cox

May 10, 2011

News Conference News

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

Caitlin E. Cox

April 05, 2011

News Daily News

Cilostazol Reduces Repeat Revascularizations for Long Lesions

March 06, 2011

Advertisement

El Pantoprazol No es Necesariamente un PPI Seguro para Pacientes a Tratamiento con Terapia Antiplaquetaria Doble

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

El Apixaban Previene el ACV en Pacientes con Fibrilación Auricular con independencia de sus Antecedentes de ACV/AIT

Apixaban Prevents Stroke in A-fib Patients Irrespective of Previous Stroke/TIA

Meta-Analysis: Adjunctive Cilostazol Lowers Repeat Revascularization After PCI

Meta-Análisis: Cilostazol Adyuvante Reduce la Necesidad de Volver a Revascularizar tras una PCI

Nuevo Análisis PLATO: Las dosis de Aspirina podrían Explicar los Resultados Discordantes de Norteamérica

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

The Value of Dual Antiplatelet Therapy During and After Endovascular Procedures: Results of a Randomized Trial - The MIRROR Study

Six Months Sufficient for Dual Antiplatelet Therapy

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Long-term Antiplatelet Therapy: All Risk, No Benefit

Prior Medication Adherence Predicts Post-PCI Clopidogrel Compliance

Adding Omega-3 Fatty Acids to Dual Antiplatelet Therapy May Reduce Thrombotic Risk

Since COURAGE, Little Change in Optimal Medical Therapy for Stable PCI Patients

EXCELLENT Outcomes Regardless of Antiplatelet Therapy Duration After DES

Cilostazol Reduces Repeat Revascularizations for Long Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content